Arca
Skip to content

Primary myelofibrosis (pmf)

Drug research and approvals for primary myelofibrosis (pmf): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 8 studies of primary myelofibrosis (pmf) are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, FDA has 3 approved and 1 open orphan designations naming it, and the EU has 5 authorised medicines for it.

  • Recruiting worldwide: 8
  • Trials authorized in Canada: 8
  • FDA orphan approvals: 3
  • EU medicines: 5

Recruiting Now

Newest start dates first, of 8 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
May 1, 2025A randomized, double-blind, placebo-controlled multicenter phase 3 clinical study to assess efficacy and safety of ropeginterferon alfa-2b (p1101) in adult…ROPEGINTERFERON ALFA-2B-NJFT (P1101)PharmaEssentiaOngoing
Nov 29, 2019A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…PACRITINIB (SB1518) / RUXOLITINIB / HYDROXYUREA / DANAZOLSobiOngoing
Jul 27, 2018An open-label, phase 2a/2b study of krt-232 in subjects with primary myelofibrosis (pmf), post¿polycythemia vera mf (post¿pv-mf), or post¿essential…NAVTEMADLIN (KRT-232)KARTOS THERAPEUTICS INCOngoing
Feb 28, 2018Extended access of momelotinib for subjects with primary myelofibrosis (pmf) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis…MOMELOTINIBGSKClosed
Jan 10, 2017A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients.JAKAVI (INC424, RUXOLITINIB)Novartis Pharmaceuticals CorporationClosed
May 9, 2014A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…PACRITINIB (SB1518)CTI BIOPHARMA CORPOngoing
Feb 6, 2014A phase 3, randomized, double-blind active-controlled study evaluating momelotinib vs. ruxolitinib in subjects with primary myelofibrosis (pmf) or…MOMELOTINIBGilead SciencesClosed
Jul 19, 2013A phase 2, open-label, prospective study of prm-151 in subjects with primary myelofibrosis (pmf), post-polycythemia vera mf (post-pv mf), or post-essential…PRM-151 SOLUTION FOR INJECTION (RO7490677)RocheClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Feb 28, 2022VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)…Sobi, Inc.Approved
Aug 16, 2019INREBICINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or…Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene CorporationApproved
Nov 16, 2011JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis…Incyte CorporationApproved
Dec 14, 2020Jaktinib Dihydrochloride MonohydrateTreatment of Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Suzhou Zelgen Biopharmaceuticals Co., Ltd.Designated

Medicines Authorised in the EU

Newest first
Nov 12, 2026Ruxolitinib Zentivaruxolitinib · genericZentiva k.s.EMA ↗
Sep 18, 2026Ruxolitinib Viatrisruxolitinib hemifumarate · genericViatris LimitedEMA ↗
Jan 25, 2024Omjjaramomelotinib · orphanGlaxoSmithKline Trading Services LimitedEMA ↗
Feb 8, 2021Inrebicfedratinib · orphanBristol Myers Squibb Pharma EEIGEMA ↗
Aug 23, 2012JakaviruxolitinibNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.